Xerataus

About Xerataus

Xerataus is a healthcare technology firm operating as a subsidiary of Leighton Dynamica, focused on the application of artificial intelligence for medical advancements. The company was established in 2022 by Tristan Leighton, an entrepreneur who also founded the parent company, Leighton Dynamica. Mr. Leighton's background includes a Master of Science in Computer Sciences and Information Technologies from the University of Miami, and he has experience in healthcare intelligence and artificial intelligence. Based in Miami, Florida, Xerataus is developing a platform aimed at the oncology sector.

The core of Xerataus's business is a dynamic healthcare system designed to assist in creating personalized cancer therapies. The technology leverages what the company refers to as "Amalgamated Composite Artificial Intelligence" to analyze patient data. Composite AI is an approach that combines multiple AI techniques—such as machine learning, natural language processing, and knowledge graphs—to solve complex problems more effectively than a single AI method could. By integrating these different technologies, the system can analyze varied datasets to identify optimal treatment paths, with the stated goals of improving patient outcomes and reducing associated costs. The business targets healthcare companies, providing them with advanced analytical tools.

Xerataus has secured significant early-stage funding to support its development and operations. The company raised a total of $75 million through three separate pre-seed and seed funding rounds in 2023, with IO Group listed as a primary investor. These funding rounds occurred in March, August, and September of 2023, each contributing $25 million. The company is positioned within the HealthTech and SaaS verticals, with a specific emphasis on oncology.